Plasma IL-23 could be regarded as possible biomarker of CHC-NSF patients in comparison with controls, while plasma IL-6 and IL-17A could be biomarkers of CHC-SF patients in comparison with controls. This evidence concerns the gene IL17A and cryohydrocytosis.